CARsgen Therapeutics, Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2014)

Organization Overview

First Clinical Trial
2016
NCT02876978
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CARsgen Pharmaceuticals Co.,Ltd | CARsgen Therapeutics Co., Ltd. | Carsgen Therapeutics, Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Esophageal Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Pancreatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 22
  • # of Trial APIs: 15